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Abstract
Persistent elevation of aspartate aminotransferase (AST) activity in serum due to the presence
of a macro-enzyme form of AST (macro-AST) may lead to diagnostic confusion in many clinical
conditions, particularly in those associated with chronic liver disease. We present a case of
macro-AST in a patient with non-alcoholic fatty liver disease in which polyethylene glycol
precipitation confirmed the cause of disproportionately elevated AST as macro-AST.
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Introduction
Macro-enzymes are high molecular mass complexes of plasma enzymes with immunoglobulins
(e.g., IgG, IgA or IgM) or other plasma components [1]. They are formed as a result of immune
dysregulation. Their reduced plasma clearance and prolonged half-life results in elevated
serum activities due to the “trapping” of enzymes in serum and reflect as unusually high values
on laboratory investigations without a plausible explanation.
Isolated elevation of aspartate aminotransferase (AST) due to macro-enzyme-AST (macro-AST)
is a benign and rare condition [2]. Because of its rarity, macro-enzyme testing is not routinely
performed in clinical practice. Therefore, the diagnosis is often delayed with a prolonged work-
up and may include invasive evaluations like a liver biopsy. We report a case of isolated AST
elevation with non-alcoholic fatty liver disease due to the presence of macro-AST.
Case Presentation
A 46-year-old African-American woman was referred to our hepatology clinic for evaluation of
abnormal liver enzymes detected on routine blood work. The elevated AST level of 136 U/L was
first noted in 2006, and other liver enzymes were within reference ranges. Subsequent
measurements showed an upward trend for persistent AST elevation, as shown in Figure 1.
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FIGURE 1: Persistent and disproportionate elevation of AST
compared to ALT for over a decade.
Enzyme (reference range):
Total bilirubin (0.1-1.0 mg/dL)
Alk. Ph.: alkaline phosphatase (30-110 U/L)
AST: aspartate aminotransferase (0-45 U/L)
ALT: alanine aminotransferase (0-55 U/L)
 
The physical examination was unremarkable, and the patient had no stigmata of liver disease.
A review of her laboratory data revealed disproportionately elevated AST levels. A
comprehensive work-up for elevated AST including screening for hemolysis, acute and chronic
viral hepatitis, autoimmune hepatitis, alpha-1 antitrypsin, ferritin levels, creatine kinase (CK),
and aldolase was unrevealing.
An ultrasound and computed tomography (CT) scan revealed a normal liver, spleen, and
pancreas on two separate occasions, with one year between the scans. Liver biopsy findings
were suggestive of steatohepatitis, as shown in Figure 2.
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FIGURE 2: Liver biopsy showing steatohepatitis (yellow arrow),
steatosis, moderate ballooning (blue arrow). No fibrosis or iron
stores seen.
As the tests did not reveal the cause of the unusually high AST levels, macro-AST was
suspected. To confirm this, a blood sample was tested for macro-AST by the polyethylene glycol
(PEG) precipitation method. Serum AST activity before precipitation was 808 U/L, but it
dropped to 24 U/L post-PEG precipitation. The results were consistent with the presence of
macro-AST (i.e., 97% of the activity is precipitated with PEG), confirming our diagnosis.
Discussion
Several enzymes (e.g., amylase, CK, lactate dehydrogenase, and AST) complexed with
immunoglobulins have been described in the literature as macro-enzymes, with macro-
amylasemia being the most frequently reported. The incidence of immunoglobulin-complexed
AST has not yet been established in the general population, but it appears low because the
biochemical methods for diagnosis are not readily available in the laboratory. 
Elevated liver enzymes, such as aspartate aminotransferase and alanine aminotransferase, most
commonly reflect hepatocellular injury, and therefore, prompt extensive serological,
radiological, and sometimes histological evaluations are required for assessment of liver
disease. The most common conditions to be ruled out include alcoholic hepatitis, viral
hepatitis, hemochromatosis, autoimmune hepatitis, Wilson's disease, alpha-1 antitrypsin
deficiency, medication use and congestive hepatopathy. The patient should be tested for
hepatitis B and C, serum iron studies, autoantibodies, serum ceruloplasmin and serum alpha-1
antitrypsin levels. When no liver-related etiology is found, attention should be diverted to
extra-hepatic sources of injury such as rhabdomyolysis and hemolysis, and the patient should
be tested for myoglobinuria and peripheral blood smear study and serum haptoglobin levels.
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An isolated or disproportionate elevation in AST in the absence of these processes warrants an
evaluation of macro-AST [3].
Macro-AST is typically a diagnosis of exclusion. The clinician should be aware of the possibility
of this diagnosis and retain a high index of suspicion for this condition. Thorough patient
history and routine laboratory tests are important to ensure that no associated or coexisting
condition explains the elevated AST levels. The next step is confirmatory diagnostic testing
such as assessing protein electrophoresis, precipitation with PEG, exclusion gel filtration
chromatography, or activation assays with pyridoxal-5-phosphate [4-6].
We found no discernible etiology for macro-AST in our patient. Therefore, we concluded that it
was a benign elevation of macro-AST that manifested incidentally. The treatment involved
reassurance with routine monitoring of liver enzymes.
Conclusions
This case illustrates the need to consider macro-AST as a cause of persistent or
disproportionate elevation of AST in a patient with non-alcoholic steatohepatitis. The use of
PEG is a simple and effective method for detecting macro-enzymes; it is a highly sensitive and
specific test but is not widely available. This report emphasizes the need for a high clinical
index of suspicion and early testing for macro-AST to avoid unnecessary expensive and
invasive investigations. The presence of macro-AST is not a transient phenomenon, and
elevated laboratory values attributable to immunocomplex enzymes may persist for many
years. Therefore, a thorough documentation in patient notes is vital to avoid future diagnostic
dilemmas. No medication is indicated, and reassurance is the mainstay of treatment.
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